Related Experiment Video
Updated: Jul 7, 2026
10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
Gynecologic oncology in pregnancy
Frédéric Amant1, Kristel Van Calsteren, Ignace Vergote
1Gynecologic Oncology, Leuven Cancer Institute (LKI), Department of Obstetrics and Gynecology, UZ Gasthuisberg, Katholieke Universiteit Leuven, Belgium. Frederic.amant@uz.kuleuven.ac.be
Critical Reviews in Oncology/Hematology
|February 26, 2008
Summary
Pregnancy does not worsen gynecological cancer prognosis. Treatments like surgery, chemotherapy, and radiotherapy are often safe during pregnancy, allowing fetal life to be saved in most cases.
Area of Science:
- Gynecology
- Oncology
- Maternal-Fetal Medicine
Background:
- Gynecological malignancies can occur during pregnancy.
- Management decisions require balancing maternal and fetal health.
Purpose of the Study:
- To review current knowledge on the prevalence, diagnosis, treatment, and prognosis of gynecological cancers in pregnant patients.
- To evaluate the impact of pregnancy on cancer prognosis and the safety of various treatment modalities.
Main Methods:
- Literature review of studies on gynecological cancers during pregnancy.
- Analysis of treatment options including surgery, chemotherapy, and radiotherapy.
- Discussion of tumor-specific diagnostic and treatment strategies.
Main Results:
- Termination of pregnancy does not improve prognosis for concurrent malignancies.
- Prognosis per stage is similar to non-pregnant patients; suboptimal care impacts outcomes.
- Most surgical techniques, radiotherapy (upper abdomen), and chemotherapy are generally safe during pregnancy.
Conclusions:
- Pregnancy does not inherently worsen gynecological cancer prognosis.
- Cancer treatment during pregnancy is feasible with careful consideration of trimester and modality.
- Fetal life can often be preserved, with termination indicated only in specific cases like unwanted pregnancy or advanced cervical cancer.
Related Concept Videos
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:07Oogenesis
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
01:30Hormonal Control of the Ovarian Cycle
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...